 MONMOUTH JUNCTION, N.J., Dec. 23, 2020 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced its corporate highlights and financial results for its fiscal year ended September 30, 2020. 